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Abstract
Background: Central Africa is a ‘‘hotspot’’ for emerging infectious diseases (EIDs) of global and local importance, and a
current outbreak of ebolavirus is affecting multiple countries simultaneously. Ebolavirus is suspected to have caused recent
declines in resident great apes. While ebolavirus vaccines have been proposed as an intervention to protect apes, their
effectiveness would be improved if we could diagnostically confirm Ebola virus disease (EVD) as the cause of die-offs,
establish ebolavirus geographical distribution, identify immunologically naı̈ve populations, and determine whether apes
survive virus exposure.
Methodology/Principal findings: Here we report the first successful noninvasive detection of antibodies against Ebola virus
(EBOV) from wild ape feces. Using this method, we have been able to identify gorillas with antibodies to EBOV with an
overall prevalence rate reaching 10% on average, demonstrating that EBOV exposure or infection is not uniformly lethal in
this species. Furthermore, evidence of antibodies was identified in gorillas thought previously to be unexposed to EBOV
(protected from exposure by rivers as topological barriers of transmission).
Conclusions/Significance: Our new approach will contribute to a strategy to protect apes from future EBOV infections by
early detection of increased incidence of exposure, by identifying immunologically naı̈ve at-risk populations as potential
targets for vaccination, and by providing a means to track vaccine efficacy if such intervention is deemed appropriate.
Finally, since human EVD is linked to contact with infected wildlife carcasses, efforts aimed at identifying great ape
outbreaks could have a profound impact on public health in local communities, where EBOV causes case-fatality rates of up
to 88%.
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Introduction
Emerging infectious disease (EID) epidemics and pandemics
arise without warning, even with global efforts aimed at tracking
pathogens early and at the source, a fact most recently evidenced
by the swift global spread of influenza H1N1 [1,2] and a current
outbreak of ebolavirus affecting multiple West African countries
simultaneously [3]. Most major human EIDs are of zoonotic origin
and include viral infections of both global (HIV-1, HIV-2, H1N1)
and localized significance (ebolavirus, monkeypox, Marburgvirus,
Nipah virus, severe acute respiratory syndrome [SARS]-associated
coronavirus) [2]. Systematic monitoring of people and wildlife at
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hotspots of EID is one strategy for preventing human pathogens of
animal origin from reaching a pandemic state [4]. By detecting
animal pathogens before or just as they emerge in humans, it may
be possible to mitigate against their worldwide spread [2].
Furthermore, in the case of some diseases such as Ebola virus
disease (EVD), the monitoring of wildlife disease serves as a critical
component of early warning systems aimed at preventing the
transmission of zoonotic diseases to humans [5,6]. EVD has
repeatedly passed from infected apes to hunters, leading to
multiple epidemics and 360 human deaths (463 cases) in Gabon
and the Republic of Congo (RoC) alone since 1994 [5,7–9]. More
significantly, human epidemics are often preceded by observed
animal outbreaks, underlining the human health implications of
surveillance and control of epizootics [5,6].
The International Union for Conservation of Nature (IUCN)
currently lists the western lowland gorilla (G. gorilla gorilla) as
critically endangered and cites infectious disease as one of the top
two threats to this species [10]. Ebolavirus is lethal in humans and
nonhuman primates and has been described as a significant threat
to the survival of western lowland gorillas and chimpanzees (Pan
troglodytes) in Central Africa [7,10,11]. Data from ecological
surveys in Central African ape habitats illustrate declines in ape
signs (nests, feces, prints) temporally and spatially linked with
confirmed human EVD outbreaks [12–14]. Mathematical mod-
eling suggests that, between 1983 and 2000, gorilla numbers in
Gabon dropped by more than 56%, and it is hypothesized that
infectious pathogens, including ebolavirus and Bacillus anthracis,
may contribute to gorilla mortality in Africa [10,12,15].
Despite the significance to both human and wildlife health,
direct evidence of great ape exposure to ebolavirus or other
pathogens (either by pathogen or immune response detection) is
scant, complicating our ability to monitor epizootics. Therefore, to
fill this gap, there is a need for prospective epidemiologic studies
combining ecological data with laboratory screening. Most
currently available data regarding primate pathology and immune
response comes from experimentally infected laboratory macaques
[16,17].
In direct response to the challenges associated with collecting
blood or tissue from wildlife, non-invasively collected biological
samples such as feces have been used for wildlife disease screening
[18,19]. Primate feces have been screened for the presence of viral
nucleic acids due to shedding of simian immunodeficiency virus
(SIV), circoviruses, enteroviruses and hepatitis viruses [20–23].
For SIV, feces have also shown the presence of virus-specific
antibodies [23]. We developed a non-invasive immunological
assay to detect ebolavirus antibodies in great ape feces, allowing
us more insight into wild ape ebolavirus infections and their
surveillance, and leading the way to identifying the best
approaches for their protection. In addition, this new assay
may prove valuable in the development and employment of




Eighty gorilla fecal samples were collected in 5 different habitats
in the RoC. In zone A, 20 gorilla fecal samples were
opportunistically collected while following habituated gorillas
roughly 2 and 3 years after ebolavirus infection was confirmed
in ape carcasses at that site using a combination of RT-PCR,
immunohistochemistry and antigen capture [5,9].
In June 2007, 15 samples were collected in zone B1 during a
reconnaissance walk survey (recces) composed of eight ,10 km
linear recces radiating every 30u from a central point with terminal
ends of every other pair connected by 8 km recces. This zone is
southwest of the Mambili River in the southeastern-most area of
Odzala-Kokoua National Park (OKNP), and samples were
collected two years after two gorilla carcasses found in this area
tested positive for EBOV using RT-PCR and antigen capture
assays [9,24]. For these surveys, two teams operated simulta-
neously, each averaging 5.6 km per day over 5 days, and following
pre-determined global positioning system (GPS) points. A contin-
uous GPS track log was maintained and uploaded to a Garmin
12XL GPS (www.garmin.com) with a position recorded every
1 km.
Three missions occurred in zone B2. The first occurred from
30th August to 8th September 2005 when a 45 km closed loop
survey was conducted on the northeast side of the Mambili River.
This search was for evidence that would indicate that the above-
described May 2005 epizootic southwest of the Mambili River had
also affected wildlife on the opposite side of the waterway. Ten
gorilla fecal samples were collected and a continuous GPS track
log was maintained and uploaded to a Garmin 12 XL unit, with
points taken every 5 km. Also, in 2005, a large-scale ecological and
large mammal survey was conducted throughout OKNP under
the auspices of the Wildlife Conservation Society and the Projet
Espèces Phares of the European Union [25]. From September 5th
to 11th, 2005, five gorilla fecal samples were collected during these
missions by means of reconnaissance walk surveys and of a
systematic unbiased line transect design aimed to estimate animal
abundance derived from the density of animal sign, multipliers
decay rate and production, and the area of the survey zone; both
designed with and analyzed by the Distance software program
[26–28]. Lastly, in June 2007, the original 45 km loop described
above was repeated during which 5 gorilla fecal samples were
collected.
In November–December 2007 (Zone D) and March–April 2008
(Zone C), reconnaissance walk surveys, similar to the approach
applied in zone B1, were conducted in great ape habitats that, by
the end of the study period, had no reported disease outbreaks.
The purpose of these missions was to estimate ape abundance by
recording all ape nests. GPS points were taken every 5 km and 25
samples were collected.
Author Summary
Ebolavirus causes deadly outbreaks in wild great apes, and
has been reported as a significant threat to the survival of
wild lowland gorillas in Central Africa. Improved knowl-
edge of basic information regarding geographic distribu-
tion of ebolavirus in great ape populations, including the
identification of immunologically naı̈ve populations and
the determination of whether apes survive virus exposure,
will be needed in order for protective interventions such as
immunization to be effective. However, monitoring
ebolavirus infection in wild gorillas by current methods is
challenging because of the difficulty in obtaining diag-
nostic samples from these elusive primates. Additionally,
there are limitations associated with the available labora-
tory assays used to document ebolavirus infection. Here
we report the first successful noninvasive detection of
EBOV immunity in wild great apes, demonstrating survival
in this species. This tool will be useful in a comprehensive
strategy aimed at the protection of this endangered
species and improved prevention of EVD outbreaks in
human populations.
Monitoring Exposure to Ebolavirus in Great Apes
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Sample collection and preservation
Sample collectors wore disposable latex gloves and surgical
masks while collecting feces. Approximately 20 g of fresh feces was
placed in 20 ml of RNAlater (Qiagen GmbH, Hilden, Germany)
in a 50 ml plastic screw-top vial (Corning Incorporated, Corning,
New York, USA), sealed with Parafilm (Pechiney, Menasha, WI,
USA), and placed in zip-closure plastic bags and stored at ambient
temperature (,28uC or 82uF). Samples collected in zone B1 were
placed in liquid nitrogen vapor in a dry shipper (Arctic Express
Dual 10, Thermolyne) at the end of each day and maintained in
this state until arrival at the analyzing laboratory. Feces were
determined to be that of gorillas when recovered under one of the
following conditions: post-observation collection (after seeing
gorillas) or post-audition collection (after hearing gorillas), in
association with gorilla nests or in association with gorilla trails
[29,30]. Genotype studies have demonstrated that feces collected
using these methods are accurately classified as gorilla feces 98%
of the time [30]. In addition, the presence of long tri-lobed
sections, ample fiber, and abundant green leafy material further
classified these samples as gorilla dung [31,32]. Only feces
estimated to be less than 24 hours old using published criteria
[32] were collected.
NP antigen preparation
The plasmid encoding EBOV NP is a p1012 derivative [16]. To
purify the recombinant viral protein, plasmid p1012NP was tagged
at the C-terminus by site-directed mutagenesis with the Quick-
Change XL Site-directed Mutagenesis kit (Stratagene, La Jolla,
CA, USA). p1012NP was provided with the hexa-histidine tag.
The tagged plasmids were transfected into human embryonic
kidney cells (FreeStyle 293-F Cells, Catalog No. R790-07)
obtained from Invitrogen (Carlsbad, CA) and grown in a shaking
flask at 37uC under 8% CO2 with FreeStyle 293 Expression
Medium (Invitrogen). The EBOV His-tagged NP was purified by
nickel-affinity gel, Ni Sepharose 6 Fast Flow (GE Healthcare,
Piscataway, NJ), and eluted with 400 mM imidazol. The
concentration of purified NP protein was measured with Quick
Start Bradford Protein Assay reagent (Biorad, Hercules, CA, USA)
and used in the western blot assay.
Western blot assays
To screen nonhuman primate fecal samples for ebolavirus
antibodies, we adapted an existing enhanced chemiluminescent
western blot assay [23]. Feces were vigorously mixed in RNAlater
(Ambion Life Technologies, Grand Island, NY, USA), 1.5 ml of
the mixture diluted in 7.5 ml of PBS-Tween-20 (0.05%), heated at
60uC for 60 minutes, centrifuged at 35006g for 20 minutes and
dialyzed in PBS 1X with stir bar at 4uC for 18 to 24 hours to
resuspend fecal immunoglobulins that normally precipitate in
RNAlater. Purified or cell lysate NP protein was denatured in
Sample Reducing Agent (Invitrogen NuPAGE), heated at 70uC
for 10 minutes, separated by 4–12% gradient sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (0.25 mg
per well) (Invitrogen NP0321, Carlsbad, California, USA), and
followed by transfer to nitrocellulose membrane (Invitrogen
LC2001, Carlsbad, California, USA) which was blocked with
5% nonfat milk in PBS-Tween (0.3%) and bovine albumin (2.4%).
Membranes were then cut into strips and incubated overnight in
fecal extract on a rocking plate. Specific NP-bound antibody was
detected with goat-anti-human IgG peroxidase conjugate and the
blot was visualized using an enhanced chemiluminescence
detection system. The films were exposed to the immunoblot
strips then scanned using an Epson Perfection 4870 Photo scanner.
To define a cut-off of positivity we used the Image J program
(ImageJ, NIH, Bethesda, Maryland, USA) that allowed us to
subtract the background in each strip and to compute the
integrated density of the band that is the sum of the values of the
pixels in the selection in the blot. Specimens which showed no
visible specific band in the blots were scored as negative whereas
those which showed specific band (reactivity with a protein of
approximate molecular mass of 115 kDa corresponding to EBOV
nucleoprotein NP) were regarded as positive if their integrated
density was in excess of the mean of integrated density plus 3
standard deviations of the negative blots. Blots with a weak specific
visible band and an integrated density below this cutoff were
classified as uncertain. A subset of samples collected in 2005 (the
year of the last EVD outbreak in the region) was also screened for
the presence of filovirus RNA using a nested RT-PCR. Fifty
nanograms of total RNA isolated from RNAlater preserved fecal
samples were extracted using the RNAqueous 4PCR kit (Ambion
Life Technologies, Grand Island, NY, USA) and used in a one-
step RT-PCR, followed by a nested PCR step. We used
degenerate primer pairs in order to amplify a 245 bp fragment
of the L polymerase gene from any Filovirus. The one step RT-
PCR primers are: 59- ATMGRAAYTTTTCYTTYTCATT-39
and 59RYTATAAWARTCACTRACATGCAT-39; the nested
PCR primers are 59-TTYCCWAGYAAYATGATGGT-39 and
59- GGDATTRDRWARTGCATCCA-39.
To assess the quality of the total RNA from the fecal sample, we
amplified a housekeeping gene for each sample, the ß-glucuron-
idase gene (GUS, Accession number AF084552) using a nested
PCR assay. The GUS primers used for the one step RT-PCR were
59-GCTTACCACCCAGTTTGAG-39 and 59-TGGGGA-
TACCTGGTTTCATTG-39, whereas the nested primers were
59-TCAGAGCGAGTATGGAGC-39 and 59-
GCACTTTTTGGTTGTCTC-39. We generated a 253 bp frag-
ment. Positive and negative controls were included to ensure that
cDNA product could be amplified and that no contamination
from cDNA or previous PCR products occurred.
Statistical analysis
We compared antibody prevalence between sampling locations
using a log-likelihood ratio test (G-Test) [33]. A 95% confidence
interval (CI) was constructed for the prevalence.
Results
Detection of ebolavirus antibodies in fecal samples
In order to examine ebolavirus exposure in wild great apes
we sought to develop a strategy of detection in samples
collected by non-invasive methods that would be sensitive and
specific enough to detect multiple ebolavirus species with
minimal false positive results. It has been shown previously that
an enhanced chemiluminescent western immunoblot assay is
able to successfully detect specific antibodies in RNAlater-
preserved feces from simian immunodeficiency virus-infected
chimpanzees (SIVcpz) [23]. The sensitivity and the specificity
of SIVcpz antibody detection in fecal samples were estimated to
be 92% and 100%, respectively. Viral SIVcpz nucleic acid
could be amplified in an immunoblot-positive fecal sample,
confirming SIVcpz infection [23]. Furthermore, a similar
approach was used to diagnose simian foamy virus infection
in wild chimpanzees (SFVcpz). The sensitivities of SFVcpz
antibody and viral nucleic acid detection in fecal samples from
captive chimpanzees were 73% and 75% respectively, and
assay specificities were 100% [34]. These studies show the
potential of assessing RNAlater-preserved fecal samples to
document wild apes’ exposure to viruses.
Monitoring Exposure to Ebolavirus in Great Apes
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Given the success of this approach, we developed a fecal western
blot assay to detect ebolavirus antibodies. We chose purified
EBOV NP as the antigen for antibody detection since it is one of
the most abundant structural proteins produced during infection
and a major target of the host immune response. This is supported
by previous studies showing that humans who have survived
natural EBOV infection developed strong antibody responses
mostly against NP [35–37]. In addition, the NP sequence is well
conserved among ebolavirus species (Figure S1), making it useful
for detection of antibodies against multiple ebolavirus species
[38,39] and potentially increasing the breadth of this detection
method.
We first assessed the ability to detect NP antibodies in
RNAlater-preserved fecal samples from captive cynomolgus
macaques. Fecal specimens were experimentally spiked with
different dilutions of positive serum containing polyclonal immu-
noglobulin from a monkey that was vaccinated with a genetic
vaccine encoding NP [16]. Serum from this vaccinated monkey
displayed antibody reactivity with NP by both ELISA and western
blot analysis (not shown).
Extracts from these positive serum-spiked feces were then used
to incubate immunoblot strips containing immobilized NP. Anti-
NP antibodies were detected by enhanced chemiluminescent
western blot immunoassay in fecal samples at seropositive
nonhuman primate (NHP) plasma dilutions of up to 105-fold
(Figure 1), indicating a high sensitivity of the assay for fecal
antibody detection. A similar level of sensitivity was observed for
detection of anti-SIV and anti-HIV antibodies by western
immunoblots using plasma samples from SIVsm-infected NHP
diluted up to 1024 and plasma samples from HIV-1 infected
individual diluted up to 1026 [40]. In contrast, fecal extracts from
captive and uninfected nonhuman primates (cynomolgus macaque
and western lowland gorilla species) treated in the same way
showed no reactivity in the NP immunoblot, demonstrating low
background for the assay and lack of cross-reactivity with serum
antibodies directed against irrelevant proteins. These results
demonstrated that NP antibodies present in primate fecal samples
can be extracted and detected by immunoblotting.
Survey of wild apes
To evaluate whether wild apes show evidence of previous
ebolavirus exposure, we screened 80 fecal samples from gorillas
living in the RoC for ebolavirus antibodies. Fecal samples were
opportunistically collected from great ape habitats using one of
two survey methodologies. The first method employed a
systematic unbiased line transect design aimed to estimate animal
abundance or the density or size of wildlife [26–28]. The second
consisted of reconnaissance walks to provide a general overview of
large animal distributions and investigate animal trails where
animal dung is likely to be encountered [41].
Fecal samples were collected from two regions within or
adjacent to OKNP in western RoC near the border with Gabon
(Figure 2). The first is an EVD diagnostically confirmed outbreak
(DCO) region where human cases were laboratory confirmed
between 2001 and 2005 [13], and ape carcasses collected between
2002 and 2005 tested positive for EBOV [5,9,24]. The presence of
long-term and functioning wildlife disease surveillance programs
and gorilla habituation and research studies in the RoC allowed
for immediate access to the DCO region during and after EVD
epidemics which facilitated the collection of 35 samples from
gorillas with a high likelihood of previous exposure to EBOV, and
samples were collected at this site within 25–43 months of
confirmed great ape EVD cases being found. The second region is
an area with no reported outbreaks at that time (NRO). Here,
there were no reported human cases, observable signs of
epidemics, EBOV-positive animal samples, or significant losses
in ape numbers despite repeated visits up until the end of this study
in April 2008. Routine and systematic reconnaissance missions for
Figure 1. Western blot detection of ebolavirus antibodies in fecal samples. The experimental limit detection of the assay was determined
by probing immunoblots with fecal extracts from experimental positive fecal samples. Western blot of immobilized NP strips showing dilutions of
cynomolgus macaque fecal extracts spiked with polyclonal serum containing NP-specific antibodies (left four lanes). Representative blots of negative
fecal extract controls from naı̈ve captive gorillas (Gor1-Gor4) and uninfected naı̈ve captive cynomolgus macaques (Cyn1-Cyn4) were included to
assess specificity. The approximate molecular weight of NP is indicated.
doi:10.1371/journal.pntd.0003143.g001
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ecological surveillance activities were used for the collection of 45
samples in the NRO region (Table 1).
Identification of ebolavirus antibodies in wild great apes
All human EVD outbreaks that had previously occurred in our
sampling zone study are thought to be the result of handling
infected wild animal carcasses, including gorillas [13]. Samples
from carcasses were used to document EBOV outbreaks in gorillas
by RT-PCR, antigen detection ELISA and immunohistochemistry
[5]. To explore whether ebolavirus antibodies could be detected in
fecal samples obtained from wild apes we focused initially on the
DCO region (zones A and B1; Figure 3) in order to maximize the
likelihood of obtaining fecal samples from apes that had been
exposed to EBOV. Among 35 fecal samples collected from the
DCO region, 5 tested positive for NP antibodies by immunoblot
(Figure 4, Table 1). Two EBOV antibody positive fecal samples
out of 20 (10%, CI: 0–26.3%) came from zone A where, in late
2002 and early 2003, EBOV was laboratory confirmed in great
ape carcasses at the Lossi Sanctuary [5,24] (Figure 2). Of 15
samples collected in zone B1 in 2007, two samples were uncertain
(defined in Methods) and three were positive for NP antibodies
(23.3%, CI: 0–47.9%). Samples were collected from zone B1
during a mission two years after ebolavirus was detected in ape
carcasses at the site [5,24] (Figure 2).
Great ape seropositivity in outbreak-free zones
We also tested ape fecal samples obtained from the outbreak-
free (NRO) region to explore whether NP antibody detection can
be used as a potential surveillance tool. The NRO region
contains zones B2, C and D. Zone B2 is adjacent to B1, yet
separated from it by the relatively large Mambili River. In the fall
of 2005, fifteen ape fecal samples were collected in zone B2 to
determine whether a May 2005 epizootic had also affected
wildlife on the opposite side of the waterway. Two years later, in
June 2007, the original 45 km closed loop track was repeated to
explore any temporal changes in ape density or NP seropositivity.
Three positive fecal samples out of twenty (15%, CI: 0–30.6%)
were found in zone B2 (Table 1) and one sample was uncertain.
Twenty-five fecal samples were collected in zone C (March and
April 2008) and zone D (November and December 2007). The
zone C mission followed the discovery of one chimpanzee carcass
that later tested negative for EBOV (E. Leroy, personal
communication, April 30, 2008). No antibodies were found in
the fecal samples from zones C and D, where no outbreaks had
been reported.
Altogether, eighty fecal samples from wild great apes were
analyzed by Western blot and eight (10%) were found to be NP
antibody positive (Table 1). Three samples (one from zone B2 and
2 from zone B1) had blots with a weak specific visible band and an
Figure 2. Confirmed human and ape Ebola virus (EBOV) infection in relation to sampling zones. Numbers in red triangles correspond to
the number of great ape carcasses previously reported to be positive for EBOV infection by more than one diagnostic test, which includes antigen
detection, DNA amplification or immunohistochemical staining. Red circles represent villages with recorded human EBOV outbreaks. Blue lines are
rivers, and the limits of the Odzala-Kokoua National Park are shown by a dashed gray line. DCO: diagnostically confirmed outbreak region (south and
west of the Mambili River). NRO: no reported outbreak region (north and east of Mambili River).
doi:10.1371/journal.pntd.0003143.g002
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integrated density below the cutoff, and were thus classified as
uncertain (not shown). The remaining 69 fecal samples showed
no detectable NP-specific antibodies and were classified as
antibody negative. Roughly half of the samples were collected in
the DCO region and 14.2% of these samples were found to be
antibody positive, whereas a smaller proportion (6.6%) of
samples collected in the NRO region were positive. The
difference between the NRO and DCO regions is not
statistically significant (log likelihood ratio statistic
(G) = 1.3925, X-squared df = 1, p-value = 0.238) (Table 1), but
overall the data show that anti-NP antibodies are present in
fecal samples from wild ape populations even in areas with no
prior reports of human or wild great ape outbreaks. These data
demonstrate that the screening of wild gorilla feces by western
blot for the purpose of monitoring ebolavirus exposure was
successful in detecting NP antibodies.
Discussion
This study represents the first time that ebolavirus antibodies
have been detected in wild great ape fecal samples, and carries
important implications for the future management and survival of
these primates. This is especially relevant because intervention
strategies to protect apes against future EVD infections are being
actively explored, including vaccination since ebolavirus vaccines
have been shown to protect laboratory monkeys from disease
[42,43].
There have been no studies or observations involving great apes
that have described immune response, clinical signs, precise
mortality rates or whether survivorship provides long-term
immunity, and little is known regarding the overall ebolavirus
serological status of apes in Central Africa. To date, serum samples
from gorillas (n = 30) and chimpanzees (n = 256) in Central Africa
Figure 3. Sampling survey zones. Upper right panel: the region in Africa from which samples were collected. Large panel: enlargement showing
collection zones; samples were collected within or adjacent to the Odzala-Kokoua National Park in western RoC near the border with Gabon and the
large panel indicates the details of the fecal sample collection zones: A and B2 are fecal sampling zones using closed loop survey or line transects
(green line) and B1, C and D are sampling zones by reconnaissance walk survey (triangle shapes) as described in Materials and Methods. The blue line
is the Mambili River. The diagnostically confirmed outbreak region (DCO) south and west of the river is in gray with dash lines and the no reported
outbreak (NRO) region north and east of the river is in gray without dash line. The border of the Odzala-Kokoua National Park is identified by a dashed
gray line.
doi:10.1371/journal.pntd.0003143.g003
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PLOS Neglected Tropical Diseases | www.plosntds.org 7 September 2014 | Volume 8 | Issue 9 | e3143
have been screened for antibodies against EBOV [7]. Most of
these animals were sampled while living in captive settings (pets,
rescue centers, primate centers); four subjects were free-ranging
and sampled directly from the wild in OKNP but were
seronegative. Obtaining samples from free-ranging wildlife is
needed to improve our understanding of infectious agents
circulating in the environment.
All other health data related to ebolavirus from free-ranging
apes comes from necropsies performed during wildlife die-offs and,
in those cases, the vast majority of samples collected are too
degraded to have diagnostic value [5]. As expected, there is also
nothing known regarding potential co-infections involved in great
ape EVD which may modify the host immune response, alter
pathogenesis, increase mortality or influence the effectiveness of
any future prophylactic plans, such as the administration of a
vaccine once available. This is due to the difficulty in acquiring
diagnostic samples from wild populations. Capture and subsequent
blood collection for serological screening is costly, time consuming,
and carries some risk to the animals while providing information
on only a few individuals. In fact, despite the disappearance of a
staggering number of great apes in Gabon and the RoC and 6
years of sustained and active surveillance in these countries during
the course of this study, only 37 carcasses were recovered, with
confirmed EBOV infection in 16 of those individuals [9–11,24].
Moreover, finding animal carcasses in vast tracts of rain forest is
difficult; it requires intensive searching and often results in the
acquisition of highly degraded samples, which are not suitable for
detection of viral antigens or nucleic acid and are more prone to
negative results [5].
This newly developed approach for non-invasive sampling of
great apes has allowed the successful detection of anti-EBOV
antibodies in fecal samples, yielding a seroprevalence rate of 10%
in gorillas. Since genetic identification of individual fecal samples
was not performed, we cannot rule out the possibility of
resampling, so the prevalence rate is an upper limit for this data
set. However, recent genetic analysis of gorilla and chimpanzee
samples collected during iron-cross recces (the type of surveillance
executed in sites B1, C, and D) from 2006–2010 suggest a low
resampling rate. Of 162 samples, three were identified with genetic
identity the same as three previously sampled individuals, yielding
a 2% resampling rate for sites in which the same site was revisited
with the shortest interval of seven-months apart; the resampling
rate in the currently study could be higher because two sites were
sampled one-month apart and two locations, A and B2, were not
iron-cross recces (personal communication, K.J. Lee)
In addition to estimating ebolavirus exposure in NHP, this
technique of screening feces by western blot is in fact a multi-
purpose tool. It provides the potential to employ serial fecal
collections to detect a temporal change in incidence exposure in a
given zone. For instance, we saw a trend toward a decrease in
ebolavirus fecal antibodies in zone B1/B2 from 20% in 2005 to
12% in 2007, which can be tested in the future using formal
prospective studies. Fecal antibody screening can also be used
before and after vaccination to demonstrate vaccine-induced
immune responses developed in great ape populations, noting that
antibody levels in vaccinated non-human primates are an immune
correlate of protection [42]. Finally, this approach will facilitate
the identification of immunologically naı̈ve populations for large-
scale vaccination trials, thereby improving cost-effectiveness by
identifying communities that could benefit the most from
vaccination efforts. Along these lines, it provides us with the first
real possibility to investigate patterns of EVD emergence in wild
apes independent of animal mortality and the role natural barriers,
such as rivers, may have in mitigating its spread. This ability to
map exposure patterns across Central Africa may also provide
insight into how this virus spreads within and between ape
populations, a question that has generated two disparate theories:
multiple virus introductions and a single spreading outbreak
[10,11,24,44].
Key to pandemic prevention is disease surveillance at the
human/wildlife interface, especially considering the fact that the
majority of emerging infectious diseases events (over 60%) are of
animal origin and that those caused by wildlife pathogens are
increasing [6,45]. The strategy described herein will be valuable in
providing zoonotic information of public health concern from
regions where resources are poor and help counter the emergence
Figure 4. Detection of ebolavirus NP antibodies in gorilla fecal samples. Fecal samples from wild gorillas were tested by enhanced
chemiluminescent western blot using strips containing immobilized Ebola virus NP. Positive samples are grouped according to the two collection
regions, diagnostically confirmed outbreak (DCO) and no reported outbreak (NRO). Strips from representative negative samples are shown. The
approximate molecular weight of NP is indicated. An experimental cynomolgus macaque fecal sample spiked with NP-positive serum was used as a
positive control (PC).
doi:10.1371/journal.pntd.0003143.g004
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of diseases which have potential to become the next pandemic.
Monitoring diseases in animals using methods such as those we
describe here allows for the identification and surveillance of many
pathogens, including those with potential to adapt and spread in
humans, like HIV and plasmodium parasites [23,46,47]. These
findings also illustrate the role in situ conservation organizations
can play in disease surveillance programs.
Adapting these tools for use in other wildlife species may
provide information regarding the transmission of ebolavirus and
other emerging infectious diseases to human populations. Recent
concerns surround the role pigs play in the emergence of diseases
such Reston ebolavirus and H1N1 [1,48]. Central Africa’s forests
are home to tens of thousands of wild pigs, including the Giant
Forest Hog (Hylochoerus meinertzhageni) and the Red River Hog
(Potamochoerus porcus), and are characterized as emerging disease
hotspots [45]. Although no evidence has emerged supporting
speculation of ebolavirus-associated wild pig die-offs in Africa,
employing this assay in these species may address whether pigs are
amplifiers, victims or carriers of the virus [48]. It is noteworthy
that in the case of influenza pigs are considered ‘‘mixing vessels’’
for viruses and capable of generating new strains transmissible to
humans [49]. The extensive bush meat trade in Africa provides
ample opportunity for pathogen transmission from pigs to
humans, and underlines the importance of disease surveillance
in this species.
Wildlife managers frequently perform wide scale ecological
surveys, simultaneously collecting biological samples and data on
the density and distribution of wildlife. With the benefit of the new
diagnostic capacity and sampling strategies described herein,
different fecal sampling approaches can be integrated into these
surveys to provide information that has thus far eluded us
concerning the distribution, ecology and epidemiology of ebola-
virus. For the first time, both the logistical and diagnostic
capacities are available to immunologically screen large popula-
tions of wild great apes for previous exposure to ebolavirus and
even estimate and monitor prevalence rates.
Supporting Information
Figure S1 Ebolavirus nucleoprotein sequences. Sequence
alignment of the nucleoprotein NP from Zaire ebolavirus (EBOV,
Accession No. NP_066243), Tai Forest ebolavirus (TAFV, Acces-
sion No. ACI28629), Reston ebolavirus (RESTV, Accession
No. BAB69003), Sudan ebolavirus (SUDV, Accession
No. AAD51107) and Bundibugyo ebolavirus (BDBV, Accession
No. ACI28620). The numbering of the amino acids is according
to their position in the sequence. ‘‘*’’, identical residues; ‘‘:’’
conserved residues; ‘‘.’’, semi-conserved residues.
(PDF)
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